| P50 | author | Bryant R England | Q56944667 |
| P2093 | author name string | Ted R Mikuls | |
| | Daniel R Anderson | |
| | Geoffrey M Thiele | |
| P2860 | cites work | Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 |
| | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study | Q24630541 |
| | Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review | Q26747207 |
| | Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist | Q26748085 |
| | Protein carbamylation and cardiovascular disease | Q26827410 |
| | Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation | Q27320563 |
| | Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis | Q28390163 |
| | Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis | Q28576951 |
| | Inflammation, atherosclerosis, and coronary artery disease | Q29547232 |
| | EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update | Q30244903 |
| | Evaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography | Q30401698 |
| | Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration | Q30885473 |
| | EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 |
| | Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy | Q33524712 |
| | Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis | Q33686973 |
| | Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis | Q33687843 |
| | Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. | Q33730073 |
| | Toll-like receptor 4 mediates endothelial cell activation through NF-κB but is not associated with endothelial dysfunction in patients with rheumatoid arthritis | Q33740199 |
| | Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis | Q33793383 |
| | Left ventricular function in treatment-naive early rheumatoid arthritis | Q33847043 |
| | Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis? | Q33868702 |
| | Mortality in rheumatoid arthritis: 2008 update. | Q34014809 |
| | Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. | Q34015846 |
| | Adipocytokines, insulin resistance, and coronary atherosclerosis in rheumatoid arthritis | Q34021686 |
| | Increased prevalence of diastolic dysfunction in rheumatoid arthritis. | Q34061175 |
| | High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis | Q34119124 |
| | Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness | Q34153114 |
| | Unique antibody responses to malondialdehyde-acetaldehyde (MAA)-protein adducts predict coronary artery disease | Q34166358 |
| | Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 |
| | Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity | Q34238357 |
| | Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study | Q39225848 |
| | Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study | Q39328180 |
| | Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors | Q39375911 |
| | Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease | Q39378053 |
| | Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. | Q39405773 |
| | Association of Rheumatoid Factors With Subclinical and Clinical Atherosclerosis in African American Women: The Multiethnic Study of Atherosclerosis. | Q39783377 |
| | Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. | Q40386790 |
| | Association of Anti-Citrullinated Peptide Antibodies With Coronary Artery Calcification in Rheumatoid Arthritis | Q40556385 |
| | Association of Light-Intensity Physical Activity With Lower Cardiovascular Disease Risk Burden in Rheumatoid Arthritis | Q40599674 |
| | Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis | Q40715496 |
| | Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis | Q40813488 |
| | Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis | Q40850003 |
| | Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis | Q40961450 |
| | Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis | Q41143656 |
| | Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study | Q41617609 |
| | Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study | Q41728784 |
| | Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial | Q41914520 |
| | Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications | Q41921823 |
| | Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients | Q41933145 |
| | Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis | Q42538647 |
| | HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis | Q42610707 |
| | Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial | Q42611547 |
| | Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans. | Q42726419 |
| | Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial | Q43062339 |
| | Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers | Q43137490 |
| | Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? | Q43255462 |
| | Elucidation of reaction scheme describing malondialdehyde-acetaldehyde-protein adduct formation | Q43674185 |
| | Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study | Q43686388 |
| | The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients | Q43714093 |
| | Antibodies to citrullinated peptides and risk of coronary heart disease | Q43934505 |
| | Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease | Q44204800 |
| | Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis | Q44453472 |
| | The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis | Q44558171 |
| | Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis | Q45129989 |
| | HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab | Q34270268 |
| | The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study | Q34272487 |
| | Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging | Q34433298 |
| | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis | Q34547253 |
| | Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis | Q34550743 |
| | Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q34582722 |
| | Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 |
| | Selection bias in rheumatic disease research | Q34662693 |
| | Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease | Q34684331 |
| | IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 |
| | Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 |
| | Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis | Q34917991 |
| | Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis | Q35070822 |
| | Role of oxidative stress in atherosclerosis | Q35088521 |
| | The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis | Q35135726 |
| | The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | Q35135831 |
| | The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores | Q35204645 |
| | Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study | Q35352554 |
| | Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. | Q35408694 |
| | Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis | Q35489690 |
| | Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis. | Q35541874 |
| | Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. | Q35564852 |
| | Burden of major musculoskeletal conditions. | Q35622610 |
| | Disease activity in rheumatoid arthritis and the risk of cardiovascular events | Q35655764 |
| | Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis | Q35669374 |
| | Endothelial Dysfunction in Rheumatoid Arthritis: Mechanistic Insights and Correlation with Circulating Markers of Systemic Inflammation | Q35892871 |
| | Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis | Q35899148 |
| | The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease | Q35904678 |
| | Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease | Q35907814 |
| | The influence of rheumatoid arthritis disease characteristics on heart failure. | Q35915244 |
| | Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study | Q35993667 |
| | Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative | Q36001551 |
| | Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. | Q36085051 |
| | Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis | Q36098818 |
| | Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy | Q36113215 |
| | Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology | Q36115574 |
| | Patients with Rheumatoid Arthritis Show Altered Lipoprotein Profiles with Dysfunctional High-Density Lipoproteins that Can Exacerbate Inflammatory and Atherogenic Process | Q36162860 |
| | Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. | Q36190844 |
| | Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. | Q36234050 |
| | Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis | Q36320021 |
| | Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs | Q36361147 |
| | Association of Elevations of Specific T Cell and Monocyte Subpopulations in Rheumatoid Arthritis With Subclinical Coronary Artery Atherosclerosis | Q36403294 |
| | Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis | Q36633235 |
| | Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial | Q36640598 |
| | Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis | Q36784192 |
| | Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial. | Q36818924 |
| | Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients | Q36877859 |
| | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. | Q36901936 |
| | Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages | Q37008144 |
| | Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis | Q37206907 |
| | Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. | Q37260123 |
| | Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis | Q37282484 |
| | Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages | Q37413355 |
| | Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation | Q37465404 |
| | Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis | Q37466366 |
| | Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study | Q37479238 |
| | Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis | Q37690126 |
| | Progression of coronary artery atherosclerosis in rheumatoid arthritis: comparison with participants from the Multi-Ethnic Study of Atherosclerosis | Q37690404 |
| | Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. | Q37691111 |
| | Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis | Q37977885 |
| | Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | Q38606033 |
| | Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging | Q38695031 |
| | Accelerated transformation of macrophage-derived foam cells in the presence of collagen-induced arthritis mice serum is associated with dyslipidemia | Q38787886 |
| | Body Mass Index, Weight Loss, and Cause-Specific Mortality in Rheumatoid Arthritis. | Q38828456 |
| | Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study | Q38937245 |
| | An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy | Q39110166 |
| | ??? | Q28295371 |
| | Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study | Q45205227 |
| | Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? | Q45235877 |
| | Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis. | Q45940053 |
| | Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. | Q45989311 |
| | Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. | Q45998671 |
| | Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. | Q46003173 |
| | Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis | Q46099951 |
| | Cholesteryl ester transfer protein in patients with rheumatoid arthritis. | Q46288748 |
| | Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study | Q46370506 |
| | Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients | Q46477622 |
| | Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. | Q46521163 |
| | Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial | Q47622915 |
| | Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries | Q47817154 |
| | Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 |
| | Individualised exercise improves endothelial function in patients with rheumatoid arthritis. | Q47886360 |
| | Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 |
| | Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study. | Q51043783 |
| | Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. | Q51126183 |
| | Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. | Q51249816 |
| | Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis? | Q51673816 |
| | Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. | Q53035221 |
| | Bone erosion is associated with reduction of circulating endothelial progenitor cells and endothelial dysfunction in rheumatoid arthritis. | Q54340309 |
| | Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor α-induced VE-cadherin cleavage. | Q54561895 |
| | Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study | Q58160099 |
| | Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis | Q59394199 |
| | Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism | Q60241022 |
| | Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus | Q60241027 |
| | Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant | Q77624106 |
| | Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study | Q79850163 |
| | Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation | Q80932706 |
| | Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis | Q82263506 |
| | Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study | Q82354836 |
| | Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells | Q83278153 |
| | Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study | Q83355833 |
| | Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s | Q83499656 |
| | Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis | Q83666899 |
| | Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase | Q83856326 |
| | Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study | Q84141759 |
| | Blockade of IL-6 and TNF-α inhibited oxLDL-induced production of MCP-1 via scavenger receptor induction | Q84343602 |
| | Disease activity and left ventricular structure in patients with rheumatoid arthritis | Q85316673 |
| | Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist | Q85451584 |
| | Brief report: lack of replication of an association between anti-citrullinated fibrinogen and subclinical atherosclerosis in patients with rheumatoid arthritis | Q85740956 |
| | Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides | Q86982567 |
| | Angiogenic T cells are decreased in rheumatoid arthritis patients | Q87050415 |
| | Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease | Q87166645 |
| | Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis | Q87248594 |
| | Gaps in Addressing Cardiovascular Risk in Rheumatoid Arthritis: Assessing Performance Using Cardiovascular Quality Indicators | Q88041807 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | k1036 | |
| P577 | publication date | 2018-04-23 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications | |
| P478 | volume | 361 | |